A group of international researchers analyzed the outcomes of multiple myeloma patients after they failed to respond to therapy with novel agents, such as Velcade, Revlimid, and thalidomide…“The study provides an estimate of the expected outcome among patients with myeloma that has stopped responding to the newly available drugs,” said Dr. Shaji Kumar from the Mayo Clinic in Minnesota and lead author of the study. “This will allow patients to compare available options and specifically evaluate clinical trial options.”

Myeloma Beacon, by Gavin McStay, 9/1/11

Tags: Cancer